Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

often rely on over-the-counter medications called anticholinergics, such as Benadryl and Unisom. Anticholinergics induce drowsiness and block the action of acetylcholine, an important ...

Many drugs commonly prescribed to the elderly have anticholinergic properties. Due to the current clinical use of drugs with mild-to-modest anticholinergic activity, the clinical manifestations of ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

The most commonly used medications to treat OAB have anticholinergic properties. Anticholinergics are competitive inhibitors of acetylcholine at muscarinic receptors (mainly the M3 receptor ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

The Drugs That May Affect Memory The study focused on anticholinergic drugs, a group of medications used to treat various conditions. These drugs are commonly prescribed for: High blood pressure ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Management acknowledged the impact of Medicare Part D redesign but highlighted mitigating factors such as strong oncology drug performance and cost-control measures. Regulatory delays for LEQEMBI ...